Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07452692) titled 'A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects' on Feb. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: Single (Outcomes Assessor).

Primary Sponsor: Corium Innovations, Inc.

Condition: Major Depressive Disorder (MDD)

Intervention: Drug: Selegiline Transdermal Delivery System

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: July 1, 2026

Target Sample Size: 230

To know more, visit https://clinicaltrials.gov/study/NCT07452692

Publish...